RMTI (Rockwell Medical, Inc. (DE) Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by RMTI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-06 | Allen Nissenson | Director | A | — | — |
| 2026-07-06 | Timothy Chole | SVP and CCO | A | — | — |
| 2026-07-06 | Joseph H Dawson | Director | A | — | — |
| 2026-07-06 | MEGAN C. TIMMINS | EVP, CLO & Secretary | A | — | — |
| 2026-07-06 | JOHN G COOPER | Director | A | — | — |
| 2026-07-06 | Joan Lau | Director | A | — | — |
| 2026-07-06 | Mark Strobeck | President and CEO | A | — | — |
| 2026-07-06 | Heather Hunter | Chief Operating Officer | A | — | — |
| 2026-07-06 | Robert S Radie | Director | A | — | — |
| 2026-07-06 | Jesse Neri | SVP and CFO | A | — | — |
| 2026-04-17 | Jesse Neri | SVP, FINANCE AND CFO | A | — | — |
| 2026-04-17 | Mark Strobeck | President and CEO | A | — | — |
| 2026-04-17 | Timothy Chole | SVP, Chief Commercial Officer | A | — | — |
| 2026-04-17 | MEGAN C. TIMMINS | EVP, CLO and Secretary | A | — | — |
| 2026-03-16 | Jesse Neri | SVP and CFO | F | — | — |
| 2026-03-16 | MEGAN C. TIMMINS | See Remarks | F | — | — |
| 2026-03-16 | Mark Strobeck | President and CEO | F | — | — |
| 2026-03-16 | Timothy Chole | SVP and CCO | F | — | — |
| 2026-03-16 | Heather Hunter | Chief Operating Officer | F | — | — |
| 2026-01-05 | Jesse Neri | SVP and CFO | Sell | — | — |
| 2026-01-05 | Heather Hunter | Chief Operating Officer | Sell | — | — |
| 2025-11-20 | Joseph H Dawson | Director | A | — | — |
| 2025-11-18 | JOHN G COOPER | Director | Sell | — | — |
| 2025-10-08 | Heather Hunter | SVP, Chief Operating Officer | Sell | — | — |
| 2025-10-01 | Timothy Chole | SVP and CCO | Sell | — | — |
| 2025-10-01 | Jesse Neri | SVP and CFO | Sell | — | — |
| 2025-10-01 | Mark Strobeck | President and CEO | Sell | — | — |
| 2025-07-03 | Jesse Neri | SVP and CFO | Sell | — | — |
| 2025-07-03 | Timothy Chole | SVP and CCO | Sell | — | — |
| 2025-07-03 | Mark Strobeck | President and CEO | Sell | — | — |
| 2025-07-02 | Jesse Neri | SVP and CFO | Sell | — | — |
| 2025-07-02 | Mark Strobeck | President and CEO | Sell | — | — |
| 2025-07-02 | Timothy Chole | SVP and CCO | Sell | — | — |
| 2025-05-21 | Allen Nissenson | Director | A | — | — |
| 2025-05-21 | Andrea Heslin Smiley | Director | A | — | — |
| 2025-05-21 | Robert S Radie | Director | A | — | — |
| 2025-05-21 | Joan Lau | Director | A | — | — |
| 2025-05-21 | JOHN G COOPER | Director | A | — | — |
| 2025-05-21 | MEGAN C. TIMMINS | EVP, CLO and Secretary | A | — | — |
| 2025-05-21 | Timothy Chole | SVP, Chief Commercial Officer | A | — | — |
| 2025-05-21 | Mark Strobeck | President and CEO | A | — | — |
| 2025-05-21 | MARK H RAVICH | Director | A | — | — |
| 2025-05-21 | Jesse Neri | SVP, FINANCE AND CFO | A | — | — |
| 2025-04-15 | Irrevocable Larson Family Investment Trust | 10%+ Owner | Buy | — | — |
| 2025-04-02 | Mark Strobeck | President and CEO | Sell | — | — |
| 2025-04-02 | Timothy Chole | SVP, Chief Commercial Officer | Sell | — | — |
| 2025-04-02 | Jesse Neri | SVP, FINANCE AND CFO | Sell | — | — |
| 2025-03-18 | Mark Strobeck | President and CEO | F | — | — |
| 2025-03-18 | MEGAN C. TIMMINS | EVP, CLO and Secretary | F | — | — |
| 2025-03-18 | Jesse Neri | SVP, FINANCE AND CFO | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 349,900 | — |
| — | President and CEO | 62,349 | — |
| — | EVP, CLO & Secretary | 31,240 | — |
| — | Chief Operating Officer | 28,007 | — |
| — | SVP and CCO | 27,285 | — |
| — | SVP and CFO | 27,239 | — |
| — | Director | 23,985 | — |
| — | Director | 23,892 | — |
| — | Director | 23,670 | — |
| — | Chairman, President and CEO | 23,181 | — |
| — | Director | 20,944 | — |
| — | 10%+ Owner | 16,466 | — |
| — | Director | 14,965 | — |
| — | Director | 14,206 | — |
| — | Director | 12,133 | — |
| — | Vice President, CFO | 6,888 | — |
| — | Sr. VP & Chief Scientific Off. | 5,225 | — |
| — | — | 3,265 | — |
| — | Chief Development Officer | 3,212 | — |
| — | Chief Executive Officer | 3,001 | — |
| — | SVP, Finance and CAO | 2,852 | — |
| — | — | 2,606 | — |
| — | Chief Medical Officer | 2,566 | — |
| — | Director | 2,389 | — |
| — | 10%+ Owner | 1,929 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RMTI quote page; the site-wide leaderboard is on the insider transactions hub.